Borderline Personality Disorder - 331-201-00242 (Otsuka)
Clinical trial to examine the efficacy and safety of brexpiprazole in patients with borderline personality disorder.
Qualified participants include:
- Adults aged 18 to 65 years old
- Have been diagnosed with borderline personality disorder
Those that qualify will:
- Receive study drug and study-related care with a board-certified psychiatrist and other clinical staff at no cost.
- Receive reimbursement for study participation and costs.
- Following the 12-week study, eligible/interested participants may choose to participate in an open-label extension study (331-201-00195, Otsuka).
Contact Ania Poltorak at 860-545-7265 or via email [email protected]